Targeting inflammatory pathways through IL-1β and TNF-α inhibitors has shown promise in reducing cardiovascular complications, and further exploration of immunomodulatory therapies may provide additional benefits in trauma-related myocardial dysfunction. Here, TNF is linked to injury.